Glenmark Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has filed a nil disclosure with NSE and BSE under SEBI's substantial acquisition regulations. Chairman and Managing Director Glenn Saldanha has declared that no promoter or promoter group, along with persons acting in concert, has created any encumbrance — directly or indirectly — on their shares during the financial year 2025-26. This is a periodic compliance filing confirming the status of promoter share pledges. No new pledges, loans against shares, or charges on promoter holdings were reported for the year.
A nil disclosure under Regulation 31(4) is generally positive for investor sentiment. It indicates that promoters have not taken on additional debt against their shareholdings, reducing the risk of forced selling pressure. Shareholders can view this as a sign of stable promoter commitment with no leverage concerns on the table.